18F-GE-180: a Novel TSPO Radiotracer Compared to 11C-R-PK11195 in a Preclinical Model of Stroke
Overview
Nuclear Medicine
Radiology
Authors
Affiliations
Purpose: Neuroinflammation plays a critical role in various neuropathological conditions, and hence there is renewed interest in the translocator protein (TSPO) as a biomarker of microglial activation and macrophage infiltration in the brain. This is reflected in the large amount of research conducted seeking to replace the prototypical PET radiotracer (11)C-R-PK11195 with a TSPO ligand with higher performance. Here we report the in vivo preclinical investigation of the novel TSPO tracer (18)F-GE-180 in a rat model of stroke.
Methods: Focal cerebral ischaemia was induced in Wistar rats by 60-min occlusion of the middle cerebral artery (MCAO). Brain damage was assessed 24 h after MCAO by T2 MRI. Rats were scanned with (11)C-R-PK11195 and (18)F-GE-180 5 or 6 days after MCAO. Specificity of binding was confirmed by injection of unlabelled R-PK11195 or GE-180 20 min after injection of (18)F-GE-180. In vivo data were confirmed by ex vivo immunohistochemistry for microglial (CD11b) and astrocytic biomarkers (GFAP).
Results: (18)F-GE-180 uptake was 24 % higher in the core of the ischaemic lesion and 18 % lower in the contralateral healthy tissue than that of (11)C-R-PK11195 uptake (1.5 ± 0.2-fold higher signal to noise ratio). We confirmed this finding using the simplified reference tissue model (BPND = 3.5 ± 0.4 and 2.4 ± 0.5 for (18)F-GE-180 and (11)C-R-PK11195, respectively, with R 1 = 1). Injection of unlabelled R-PK11195 or GE-180 20 min after injection of (18)F-GE-180 significantly displaced (18)F-GE-180 (69 ± 5 % and 63 ± 4 %, respectively). Specificity of the binding was also confirmed by in vitro autoradiography, and the location and presence of activated microglia and infiltrated macrophages were confirmed by immunohistochemistry.
Conclusion: The in vivo binding characteristics of (18)F-GE-180 demonstrate a better signal to noise ratio than (11)C-R-PK11195 due to both a better signal in the lesion and lower nonspecific binding in healthy tissue. These results provide evidence that (18)F-GE-180 is a strong candidate to replace (11)C-R-PK11195.
PET imaging of microglia in Alzheimer's disease using copper-64 labeled TREM2 antibodies.
Shojaei M, Schaefer R, Schlepckow K, Kunze L, Struebing F, Brunner B Theranostics. 2024; 14(16):6319-6336.
PMID: 39431020 PMC: 11488106. DOI: 10.7150/thno.97149.
Lithium Aspartate for Long COVID Fatigue and Cognitive Dysfunction: A Randomized Clinical Trial.
Guttuso Jr T, Zhu J, Wilding G JAMA Netw Open. 2024; 7(10):e2436874.
PMID: 39356507 PMC: 11447566. DOI: 10.1001/jamanetworkopen.2024.36874.
Cipriani R, Domerq M, Martin A, Matute C Adv Neurobiol. 2024; 37:405-422.
PMID: 39207705 DOI: 10.1007/978-3-031-55529-9_23.
Wu P, Xu L, Wang Q, Ma X, Wang X, Wang H Mol Imaging Biol. 2024; 26(4):693-703.
PMID: 38641708 DOI: 10.1007/s11307-024-01912-2.
Molecular imaging for evaluation of synovitis associated with osteoarthritis: a narrative review.
Lee K, Niku S, Koo S, Belezzuoli E, Guma M Arthritis Res Ther. 2024; 26(1):25.
PMID: 38229205 PMC: 10790518. DOI: 10.1186/s13075-023-03258-6.